Table 5.
Summary results from meta-analysis of cohort studies1
| Outcome | N studies | Median follow-up time (years) | N cases | Relative risk (95% CI) High versus low consumption | Heterogeneity (I2, P) |
|---|---|---|---|---|---|
| Total nuts | |||||
| CVD | 15 | 11.2 | 61,028 | 0.81 (0.75, 0.86) | 67.0%, P < 0.001 |
| CVD mortality | 15 | 11.2 | 44,792 | 0.77 (0.72, 0.82) | 59.3%, P < 0.001 |
| CHD | 13 | 15 | 40,549 | 0.82 (0.76, 0.89) | 64.0%, P < 0.01 |
| CHD mortality | 8 | 15 | 8,568 | 0.75 (0.65, 0.87) | 66.9%, P < 0.01 |
| Nonfatal CHD | 6 | 13.25 | 22,553 | 0.85 (0.75, 0.96) | 62.2%, P < 0.01 |
| Stroke | 10 | 12.7 | 22,635 | 0.91 (0.85, 0.97) | 24.8%, P = 0.349 |
| Ischaemic stroke | 7 | 17 | 15,421 | 0.94 (0.85, 1.03) | 36.5%, P = 0.247 |
| Stroke mortality | 6 | 9.8 | 2,566 | 0.87 (0.76, 1.00) | 0.0%, P = 0.599 |
| T2D | 5 | 12 | 24,087 | 0.95 (0.75, 1.21) | 82.25%, P = 0.003 |
| Peanuts | |||||
| CVD | 5 | 14 | 25,834 | 0.83 (0.79, 0.88) | 36.0%, P = 0.23 |
1
Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; T2D, type 2 diabetes.